Today in the News
SEE OTHER BRANDS

The latest news on global issues

Today in the News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in the News.

Press releases published on April 25, 2025

PER® Presents More Than a Dozen Free CME/CE Symposia at the Annual Oncology Meeting in Chicago

PER® Presents More Than a Dozen Free CME/CE Symposia at the Annual Oncology Meeting in Chicago

CHICAGO, April 25, 2025 (GLOBE NEWSWIRE) -- This May, during one of the most important weeks in cancer care, Physicians’ Education Resource®, LLC (PER®), the go-to educational resource for health care professionals across all specialties to advance patient …

Advanced BioNutritionals Under Review: Highly-Trusted Supplement Brand for Quality Products

Advanced BioNutritionals Under Review: Highly-Trusted Supplement Brand for Quality Products

New York City, April 25, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The most common supplement-related health concerns people face today Why supplement quality, formulation, and transparency matter more than ever How Advanced …

 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of iRobot Corporation - IRBT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of iRobot Corporation - IRBT

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  iRobot Corporation (“iRobot” or the “Company”) (NASDAQ: IRBT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RLX Technology Inc. - RLX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RLX Technology Inc. - RLX

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  RLX Technology Inc. (“RLX” or the “Company”) (NYSE: RLX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646- …

SightFresh Under Review: Secret Vision Berry to Restore Eyesight with Sight Fresh Ingredients

SightFresh Under Review: Secret Vision Berry to Restore Eyesight with Sight Fresh Ingredients

New York City, April 25, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: The hidden causes behind the sharp rise in vision problems in 2025 How digital screens, pollution, and aging contribute to visual decline What the SightFresh supplement is, …

AquaOrange Accelerates Thailand’s Cloud Adoption with Transparent Google Workspace Pricing and Local Expertise

AquaOrange Accelerates Thailand’s Cloud Adoption with Transparent Google Workspace Pricing and Local Expertise

Bangkok, April 25, 2025 (GLOBE NEWSWIRE) -- Bangkok, Bangkok - AquaOrange Software Co., Ltd. strengthens digital transformation in Thailand by offering tailored Google Workspace solutions and competitive Google Workspace price models for businesses. As …

Top Technology Executives Recognized at the 2025 HoustonCIO ORBIE Awards

Top Technology Executives Recognized at the 2025 HoustonCIO ORBIE Awards

Leading CIOs honored for leadership, innovation, and business impact.  HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- The 2025 HoustonCIO ORBIE Awards recognized the exceptional leadership and innovation of top technology executives from Chevron, NOV, Nabors, …

HPQ Silicium : Correction de communiqués antérieurs

HPQ Silicium : Correction de communiqués antérieurs

En réponse à une demande formulée par l’Autorité des marchés financiers, HPQ Silicium procède à la publication d’un communiqué rectificatif visant à corriger certaines informations à caractère prospectif diffusées dans des communiqués antérieurs. MONTRÉAL, …

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model …

Willms and Associates Named Rockford Mutual 2024 Agency of the Year

Willms and Associates Named Rockford Mutual 2024 Agency of the Year

Rockford, Illinois, April 25, 2025 (GLOBE NEWSWIRE) -- ROCKFORD, Illinois – The Willms …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of 3D Systems Corporation - DDD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of 3D Systems Corporation - DDD

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  3D Systems Corporation (“3D Systems” or the “Company”) (NYSE: DDD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Endeavour Silver Corp. - EXK

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Endeavour Silver Corp. - EXK

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM).  Such investors are advised to contact Danielle Peyton at newaction@ …

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the presentation of positive data …

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination …

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy

– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the potential for broad, deep and durable responses in hard-to-treat …

Harbinger Health Unveils Promising New Data on Early Cancer Detection Platform at AACR 2025

Harbinger Health Unveils Promising New Data on Early Cancer Detection Platform at AACR 2025

Novel analytical framework establishes a clinically meaningful performance assessment of blood-based early detection tests Innovative methodology enhances cancer signal detection, boosts specificity and predictive value Presentations further validate the …

DTE Completes Construction on Pine River Solar Park

DTE Completes Construction on Pine River Solar Park

Detroit, April 25, 2025 (GLOBE NEWSWIRE) -- DTE Energy (NYSE:DTE), Michigan’s largest producer of and investor in renewable energy, announced that construction has been completed at Pine River Solar Park during a ribbon-cutting ceremony at the site today. …

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April …

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service